Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a loss for the second quarter on Tuesday. The company posted a quarterly loss of $1.74 per share which beat the analyst consensus estimate for a loss of $2.31 per share. The company reported quarterly sales of $357.000 thousand which missed the analyst consensus estimate of $870.000 thousand. “In the second quarter we continued to advance our entire portfolio, and we are poised to soon have up to four programs in registrational stage. The Essential3 program continues to progress well, with a pre-planned interim analysis of Study 1 to be conducted later this year. We remain on track for a successful topline readout enabling an NDA filing in 2025,” said Marcio Souza, president and ...